Oxaliplatin induced laryngospasm: a case series


  • Ancy George Department of Pharmacology, Govt. Medical College Kozhikode, Kerala, India
  • Anuradha M. Department of Pharmacology, Govt. Medical College Kozhikode, Kerala, India




Oxaliplatin, Hypersensitivity, Laryngospasm


Oxaliplatin is a third-generation platinum derivative used as a first-line agent in the treatment of colorectal carcinoma, biliary tract cancer and gastric cancers and can be used as a neoadjuvant/adjuvant in these cancers. The dose limiting toxicity is peripheral neuropathy, others include hypersensitivity reactions, haematological toxicity and pulmonary fibrosis. Hypersensitivity reactions can extend from milder reactions like urticaria, rash to severe symptoms like hypotension and laryngospasm. The laryngospasm due to oxaliplatin is reported to be reversible with corticosteroids, antihistamines and oxygen. This case series suggest that oxaliplatin has a propensity to cause severe hypersensitivity reaction presenting as laryngospasm not with a single dose but with subsequent doses of oxaliplatin. Prompt symptomatic treatment with corticosteroids leads to reversal of symptoms and improvement in the condition of the patient.


Kolathu S, Lekshmi S, Pillai R, Neethu CM, Pavithran K. Oxaliplatin-induced laryngospasm - A case report. Natl J Physiol Pharm Pharmacol. 2018;8(1):146-8.

Wolmark N, Sharif S, O’Connell MJ, Yothers G, Samia LM. FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer. Cancer Invest. 2008;26(9):956-63.

Alcindor T, Beauger N. Oxaliplatin : a review in the era of molecularly targeted therapy. Curr Oncol. 2011;18(1):18-25.

Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag. 2005;1(4):249-58.

Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003;89:477-81.

Storey DJ, Sakala M, McLean CM, Phillips HA, Dawson LK, Wall Lr, et al. Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? Ann Oncol. 2010;21(8):1657-61.

Grewal GD, Badrick TC, Gilbar PJ. Immediate and delayed hypersensitivity reactions to a single dose of oxaliplatin. Clin Colorectal Cancer. 2015;14(2):128-30.

Yanai T, Iwasa S, Hashimoto H, Kato K, Hamaguchi T, Yamada Y, et al. Successful Rechallenge for Oxaliplatin Hypersensitivity Reactions in Patients with Metastatic Colorectal Cancer. Anticancer Res. 2012;5526:5521-6.

Kolathu S, Pillai R, Akhila, Pavithran K. Oxaliplatin-induced dysphonia and dysarthria- a case report. J Pharm Res. 2015;2015.

Gamelin L, Boisdron-celle M, Delva R, Ifrah N, Morel A, Gamelin E. Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions : A Retrospective Study of 161 Patients Receiving Oxaliplatin Combined with 5-Fluorouracil and Leucovorin for Advanced Colorectal Cancer. Clin Cancer Res. 2004;10(12):4055-61.




How to Cite

George, A., & M., A. (2019). Oxaliplatin induced laryngospasm: a case series. International Journal of Basic & Clinical Pharmacology, 9(1), 215–217. https://doi.org/10.18203/2319-2003.ijbcp20195790



Case Reports